Greg Caldwell

Greg Caldwell is a life sciences professional with a diverse background in strategy consulting, venture capital, and corporate finance within the biotech and pharmaceutical industries in the US and Europe.

With a passion for facilitating the growth and evolution of biotech companies, Greg's expertise spans corporate strategy, new product planning, business development, launch strategy, and organizational design.

His educational background includes a Bachelor of Arts (B.A.) in Ecology and Evolutionary Biology from Princeton University and a Master of Business Administration (MBA) from Quantic School of Business and Technology.

Greg has held various roles such as Senior Consultant at Blue Matter, Venture Partner at NextGen Venture Partners, Consultant at Blue Matter, Partner at Nodes Advisors AG, Associate at Promidian, Venture Advisor at FundRx, Analyst at Promidian, and Research Specialist at the University of Pennsylvania School of Medicine's Department of Neurosurgery.

He is driven by a commitment to driving innovation and addressing unmet needs in rare diseases and genetic disorders, with a focus on transforming biotechs from clinical to commercial success.